BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Triulzi T, Forte L, Regondi V, Di Modica M, Ghirelli C, Carcangiu ML, Sfondrini L, Balsari A, Tagliabue E. HER2 signaling regulates the tumor immune microenvironment and trastuzumab efficacy. Oncoimmunology 2019;8:e1512942. [PMID: 30546951 DOI: 10.1080/2162402X.2018.1512942] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Fu R, Tong JS. miR-126 reduces trastuzumab resistance by targeting PIK3R2 and regulating AKT/mTOR pathway in breast cancer cells. J Cell Mol Med 2020;24:7600-8. [PMID: 32410348 DOI: 10.1111/jcmm.15396] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
2 Li L, Chen M, Zheng S, Li H, Chi W, Xiu B, Zhang Q, Hou J, Wang J, Wu J. Clinical and Genetic Predictive Models for the Prediction of Pathological Complete Response to Optimize the Effectiveness for Trastuzumab Based Chemotherapy. Front Oncol 2021;11:592393. [PMID: 34336634 DOI: 10.3389/fonc.2021.592393] [Reference Citation Analysis]
3 Li JJ, Tsang JY, Tse GM. Tumor Microenvironment in Breast Cancer-Updates on Therapeutic Implications and Pathologic Assessment. Cancers (Basel) 2021;13:4233. [PMID: 34439387 DOI: 10.3390/cancers13164233] [Reference Citation Analysis]
4 Li E, Guida JL, Tian Y, Sung H, Koka H, Li M, Chan A, Zhang H, Tang E, Guo C, Deng J, Hu N, Lu N, Gierach GL, Li J, Yang XR. Associations between mammographic density and tumor characteristics in Chinese women with breast cancer. Breast Cancer Res Treat 2019;177:527-36. [PMID: 31254158 DOI: 10.1007/s10549-019-05325-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
5 Heidarpour M, Taheri M, Akhavan A, Goli P, Kefayat A. Investigation of HER-2 Expression an Its Correlation with Clinicopathological Parameters and Overall Survival of Esophageal Squamous Cell Carcinoma Patients. Iran J Pathol 2020;15:274-81. [PMID: 32944039 DOI: 10.30699/IJP.2020.113829.2235] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Chun BM, Page DB, Mcarthur HL. Combination Immunotherapy Strategies in Breast Cancer. Curr Breast Cancer Rep 2019;11:228-40. [DOI: 10.1007/s12609-019-00333-3] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
7 Bauer D, Mazzio E, Hilliard A, Oriaku ET, Soliman KFA. Effect of apigenin on whole transcriptome profile of TNFα-activated MDA-MB-468 triple negative breast cancer cells. Oncol Lett 2020;19:2123-32. [PMID: 32194710 DOI: 10.3892/ol.2020.11327] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
8 Basu A, Ramamoorthi G, Albert G, Gallen C, Beyer A, Snyder C, Koski G, Disis ML, Czerniecki BJ, Kodumudi K. Differentiation and Regulation of TH Cells: A Balancing Act for Cancer Immunotherapy. Front Immunol 2021;12:669474. [PMID: 34012451 DOI: 10.3389/fimmu.2021.669474] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Gschwandtner M, Derler R, Midwood KS. More Than Just Attractive: How CCL2 Influences Myeloid Cell Behavior Beyond Chemotaxis. Front Immunol 2019;10:2759. [PMID: 31921102 DOI: 10.3389/fimmu.2019.02759] [Cited by in Crossref: 94] [Cited by in F6Publishing: 91] [Article Influence: 31.3] [Reference Citation Analysis]
10 Janjigian YY, Kawazoe A, Yañez P, Li N, Lonardi S, Kolesnik O, Barajas O, Bai Y, Shen L, Tang Y, Wyrwicz LS, Xu J, Shitara K, Qin S, Van Cutsem E, Tabernero J, Li L, Shah S, Bhagia P, Chung HC. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature 2021;600:727-30. [PMID: 34912120 DOI: 10.1038/s41586-021-04161-3] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Moragon S, Hernando C, Martinez-martinez MT, Tapia M, Ortega-morillo B, Lluch A, Bermejo B, Cejalvo JM. Immunological Landscape of HER-2 Positive Breast Cancer. Cancers 2022;14:3167. [DOI: 10.3390/cancers14133167] [Reference Citation Analysis]
12 Shang M, Chi Y, Zhang J, Chang J, Yang H, Yin S, Tan Q, Man X, Li H. The Therapeutic Effectiveness of Neoadjuvant Trastuzumab Plus Chemotherapy for HER2-Positive Breast Cancer Can Be Predicted by Tumor-Infiltrating Lymphocytes and PD-L1 Expression. Front Oncol 2021;11:706606. [PMID: 35070953 DOI: 10.3389/fonc.2021.706606] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Huang M, Li J, Yu X, Xu Q, Zhang X, Dai X, Li S, Sheng L, Huang K, Liu L. Comparison of Efficacy and Safety of Third-Line Treatments for Advanced Gastric Cancer: A Systematic Review With Bayesian Network Meta-Analysis. Front Oncol 2021;11:734323. [PMID: 34745955 DOI: 10.3389/fonc.2021.734323] [Reference Citation Analysis]
14 Wang H, Miao J, Wen Y, Xia X, Chen Y, Huang M, Chen S, Zhao Z, Zhang Y, Chen C, Zhu X. Molecular Landscape of ERBB2 Alterations in 14,956 Solid Tumors. Pathol Oncol Res 2022;28:1610360. [DOI: 10.3389/pore.2022.1610360] [Reference Citation Analysis]
15 Li B, Geng R, Wu Q, Yang Q, Sun S, Zhu S, Xu Z, Sun S. Alterations in Immune-Related Genes as Potential Marker of Prognosis in Breast Cancer. Front Oncol 2020;10:333. [PMID: 32226776 DOI: 10.3389/fonc.2020.00333] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
16 Egal ESA, Scarini JF, de Lima-souza RA, Lavareze L, Fernandes PM, Emerick C, Gonçalves MT, Helms MN, Altemani A, Mariano FV. Tumor microenvironment in salivary gland carcinomas: An orchestrated state of chaos. Oral Oncology 2022;127:105777. [DOI: 10.1016/j.oraloncology.2022.105777] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Jin J, Lin J, Xu A, Lou J, Qian C, Li X, Wang Y, Yu W, Tao H. CCL2: An Important Mediator Between Tumor Cells and Host Cells in Tumor Microenvironment. Front Oncol 2021;11:722916. [PMID: 34386431 DOI: 10.3389/fonc.2021.722916] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
18 Meng J, Lu X, Zhou Y, Zhang M, Ge Q, Zhou J, Hao Z, Gao S, Yan F, Liang C. Tumor immune microenvironment-based classifications of bladder cancer for enhancing the response rate of immunotherapy. Mol Ther Oncolytics 2021;20:410-21. [PMID: 33665361 DOI: 10.1016/j.omto.2021.02.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
19 Kim D, Kim JM, Kim JS, Kim S, Kim KH. Differential Expression and Clinicopathological Significance of HER2, Indoleamine 2,3-Dioxygenase and PD-L1 in Urothelial Carcinoma of the Bladder. J Clin Med 2020;9:E1265. [PMID: 32349330 DOI: 10.3390/jcm9051265] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
20 Decker JT, Kandagatla P, Wan L, Bernstein R, Ma JA, Shea LD, Jeruss JS. Cyclin E overexpression confers resistance to trastuzumab through noncanonical phosphorylation of SMAD3 in HER2+ breast cancer. Cancer Biol Ther 2020;21:994-1004. [PMID: 33054513 DOI: 10.1080/15384047.2020.1818518] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
21 Le Naour J, Galluzzi L, Zitvogel L, Kroemer G, Vacchelli E. Trial watch: IDO inhibitors in cancer therapy. Oncoimmunology 2020;9:1777625. [PMID: 32934882 DOI: 10.1080/2162402X.2020.1777625] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 12.5] [Reference Citation Analysis]
22 Mercogliano MF, Bruni S, Elizalde PV, Schillaci R. Tumor Necrosis Factor α Blockade: An Opportunity to Tackle Breast Cancer. Front Oncol 2020;10:584. [PMID: 32391269 DOI: 10.3389/fonc.2020.00584] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
23 Joseph C, Alsaleem MA, Toss MS, Kariri YA, Althobiti M, Alsaeed S, Aljohani AI, Narasimha PL, Mongan NP, Green AR, Rakha EA. The ITIM-Containing Receptor: Leukocyte-Associated Immunoglobulin-Like Receptor-1 (LAIR-1) Modulates Immune Response and Confers Poor Prognosis in Invasive Breast Carcinoma. Cancers (Basel) 2020;13:E80. [PMID: 33396670 DOI: 10.3390/cancers13010080] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]